January 2016 in “Hair transplant forum international” Finasteride's link to health issues like male breast cancer, infertility, and prostate cancer needs more research through placebo-controlled trials to confirm.
7 citations
,
March 2011 in “Expert Opinion on Drug Safety” Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.
April 2018 in “Journal of Investigative Dermatology” The document concludes that ERBB2 mutations are common in extramammary Paget disease and may respond to systemic treatments like cancer immunotherapy.
4 citations
,
June 2013 in “The Journal of Rheumatology” The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.
November 2022 in “Journal of the Endocrine Society” Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.
September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
8 citations
,
April 2013 in “Journal of The American Academy of Dermatology” Some breast cancer patients treated with high-dose docetaxel may experience permanent hair loss.
October 2015 in “Elsevier eBooks” Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.
2 citations
,
April 2018 in “Journal of Investigative Dermatology” Intralesional chemotherapy with 5-fluorouracil and methotrexate may worsen keratoacanthoma-type skin cancer in transplant patients.
January 2026 in “Therapeutics” SCUBE3 is a potential target for cancer and alopecia treatment but is challenging to target due to its varied roles.
15 citations
,
February 2019 in “Journal of clinical medicine” Atorvastatin reversed memory problems caused by cancer drug trastuzumab and improved its cancer-fighting abilities without causing hair loss.
April 2019 in “Biometrics” The new clinical trial design is promising but needs real-world trials to test its effectiveness and possible enhancements.
14 citations
,
January 2020 in “International Journal of Biological Sciences” Multiphoton microscopy can effectively assess breast cancer treatment responses without labels.
65 citations
,
January 2017 in “Postępy Dermatologii i Alergologii” High-frequency ultrasonography is a useful but underused tool in dermatology for assessing skin cancers, monitoring diseases, and evaluating treatments.
21 citations
,
July 2011 in “Journal of the American Academy of Dermatology” A man developed a rash similar to pityriasis rubra pilaris after starting sorafenib for cancer, possibly due to the drug's effect on skin cells.
5 citations
,
November 2024 in “Cells” Fish cell spheroids are a promising tool for replicating real-life conditions in research.
1 citations
,
September 2025 in “The Oncologist” Effective management of side effects is crucial for safe use of sacituzumab govitecan in advanced breast cancer treatment.
May 2018 in “The Journal of urology/The journal of urology” The document highlights recent findings and treatments in urology, including prostate cancer diagnostics, urinary incontinence, and new therapies.
April 2021 in “Journal of Investigative Dermatology” Stem cells control their future role by changing ERK signal timing, affecting tissue regeneration and cancer.
12 citations
,
December 2023 in “Journal of Applied Pharmaceutical Sciences and Research” Caffeine boosts alertness, helps breathing, acts as a diuretic, and may aid cancer treatment.
25 citations
,
March 2018 in “Journal of oncology practice” Scalp cooling is an effective and safe way to prevent hair loss from chemotherapy, with manageable side effects and low risk of scalp cancer.
13 citations
,
June 2008 in “International Journal of Dermatology” Sorafenib can cause a unique skin reaction.
January 2025 in “ARC Journal of Urology” Cutaneous vesicostomy and cystoscopic valve ablation both have pros and cons for managing posterior urethral valves.
45 citations
,
January 2007 in “Journal of Clinical Oncology” Sorafenib may cause hand-foot and stump syndrome, requiring early detection and management.
May 2021 in “Journal of the Endocrine Society” The patient's hypothyroidism improved with medication adjustments and careful management.
4 citations
,
October 2018 in “Journal of Mind and Medical Sciences” Managing malignant ureteral obstruction is challenging and requires personalized treatment to protect kidney function and patient health.
3 citations
,
August 2023 in “Drug safety” Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
December 2025 in “Biomolecules” Compound 7p shows strong potential as an anticancer agent.
4 citations
,
July 2025 in “Organoids” Organoids can revolutionize medicine by modeling diseases and aiding in personalized treatments.
January 2026 in “Frontiers in Drug Discovery” Transforming skin disease treatment requires new strategies, better drug models, and patient-focused research.